F
Fred Nyberg
Researcher at Université de Sherbrooke
Publications - 9
Citations - 425
Fred Nyberg is an academic researcher from Université de Sherbrooke. The author has contributed to research in topics: Receptor & Agonist. The author has an hindex of 4, co-authored 9 publications receiving 395 citations.
Papers
More filters
Journal ArticleDOI
Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist.
Yiqian Wan,Charlotta Wallinder,Bianca Plouffe,Hélène Beaudry,A. K. Mahalingam,Xiongyu Wu,Berndt Johansson,Mathias Holm,Milad Botoros,Anders Karlén,Anders Pettersson,Fred Nyberg,Lars Fändriks,Nicole Gallo-Payet,Anders Hallberg,Mathias Alterman +15 more
TL;DR: The first druglike selective angiotensin II AT(2) receptor agonist (21) with a K(i) value of 0.4 nM with a bioavailability of 20-30% after oral administration and a half-life estimated to 4 h in rat, induces outgrowth of neurite cells, stimulates p42/p44(mapk), and enhances in vivo duodenal alkaline secretion in Sprague-Dawley rats.
Journal ArticleDOI
New Selective AT2 Receptor Ligands Encompassing a γ-Turn Mimetic Replacing the Amino Acid Residues 4−5 of Angiotensin II Act as Agonists
Ulrika Rosenström,Christian Sköld,Bianca Plouffe,Hélène Beaudry,Gunnar Lindeberg,Milad Botros,Fred Nyberg,Gunter Wolf,Anders Karlén,Nicole Gallo-Payet,Anders Hallberg +10 more
TL;DR: The pseudopeptides selected for agonist studies were shown to act as AT(2) receptor agonists being able to induce outgrowth of neurite cells, stimulate p42/p44(mapk), and suppress proliferation of PC12 cells.
Journal ArticleDOI
Angiotensin II Pseudopeptides Containing 1,3,5-Trisubstituted Benzene Scaffolds with High AT2 Receptor Affinity
Jennie Georgsson,Christian Sköld,Bianca Plouffe,Gunnar Lindeberg,Milad Botros,Mats Larhed,Fred Nyberg,Nicole Gallo-Payet,Adolf Gogoll,and Anders Karlén,Anders Hallberg +10 more
TL;DR: It is concluded that the 1,3,5-trisubstituted benzene rings can be conveniently prepared and are suitable as gamma-turn mimics and a tentative agonist model is proposed for AT2 receptor activation by angiotensin II analogues.